Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Omicron as severe as other COVID variants -large U.S. study

Published 05/05/2022, 04:57 PM
Updated 05/05/2022, 05:16 PM
© Reuters. A woman takes a coronavirus disease (COVID-19) test at a pop-up testing site as the Omicron coronavirus variant continues to spread in Manhattan, New York City, U.S., December 27, 2021. REUTERS/Jeenah Moon

(Reuters) - The Omicron variant of the SARS-CoV2 virus is intrinsically as severe as previous variants, according to a preprint version of a large U.S. study that counters assumptions in other studies that it was more transmissible but less severe.

The findings, which estimated Omicron's severity after accounting for the impact of vaccines, should reinforce the importance of inoculations and booster shots, experts said. Vaccines helped keep hospitalizations and deaths relatively low during the Omicron surge compared with previous variants.

The study, which is undergoing peer review at Nature Portfolio, was posted on Research Square on May 2. The authors, from Massachusetts General Hospital, Minerva University and Harvard Medical School, declined to comment until peer review is completed.

"We found that the risks of hospitalization and mortality were nearly identical" between the Omicron era and times in the past two years when different variants were dominant, the researchers said in their report.

The new study, based on records of 130,000 COVID patients in Massachusetts, is unique and "pretty strong," said Dr. Arjun Venkatesh of Yale School of Medicine and the Yale Center for Outcomes Research and Evaluation, who was not involved in the research.

Rather than just looking at numbers of deaths and hospitalizations, as earlier studies have done, it accounted for patients' vaccination status and medical risk factors and compared similar groups of people, Venkatesh said.

The authors cited potential limitations in their report, including the possibility that the analysis underestimated the number of vaccinated patients in more recent COVID waves, and the total number of infections, because it excluded patients who performed at-home rapid tests.

The study did not account for treatments patients may have received, such as monoclonal antibodies or antiviral drugs "that are known to reduce hospitalizations," Venkatesh noted. "It's possible that if we didn't have these treatments available today, Omicron would be even worse."

Countries around the world have found that a significant percentage of their citizens were unwilling to get a COVID vaccine, even during surges of apparently deadlier variants.

When the Omicron variant was first identified late in 2021, public health officials said it caused much milder symptoms in the vast majority of infected people. That may have encouraged the vaccine hesitant that they were less in need of a shot.

© Reuters. A woman takes a coronavirus disease (COVID-19) test at a pop-up testing site as the Omicron coronavirus variant continues to spread in Manhattan, New York City, U.S., December 27, 2021. REUTERS/Jeenah Moon

But Venkatesh said the new preprint adds to evidence that vaccines helped spare people from the worst impacts of Omicron.

"Don't make the mistake" of thinking vaccines and boosters are not important, he said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.